Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. - Wikidata - awgldk - TriplyDB

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.

http://www.wikidata.org/entity/Q33994570

about

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance Systems Toxicology: Real World Applications and Opportunities.From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine.Highlights From the American Association of Pharmaceutical Scientists/ International Transporter Consortium Joint Workshop on Drug Transporters in Absorption, Distribution, Metabolism, and Excretion: From the Bench to the Bedside - Clinical Pharmaco Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotec Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability Parsing interindividual drug variability: an emerging role for systems pharmacology.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.A Tutorial on Pharmacodynamic Scripting Facility in Simcyp.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.Using a Systems Pharmacology Approach to Study the Effect of Statins on the Early Stage of Atherosclerosis in Humans.Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.

P2860

Q24273350-DCC8ECB8-4E7F-47A0-B01B-8A5AFE891034 Q26739743-3C48505F-EA68-4024-A90D-F79F218C51C0 Q26745824-7FB1DD07-F4D1-4A7A-9989-FE5387536A26 Q33577370-5BF03FF5-BA09-4AF7-B2EE-A33C3EC6E2DA Q33600357-F310A42B-7655-4805-B6D3-A3F0143410C2 Q33782972-5323C14A-85F7-4331-951D-A0A794E23F1A Q33875931-649A546A-7013-46DC-9CDD-23FC900E0DBE Q34574831-0AC5549D-4D66-4FC2-AA96-9D2007E09585 Q36417380-FC691C41-7D3A-4B6B-9FD7-D9A990218AD6 Q37279044-2D24F3E4-4321-4349-B74B-8FACBFE03497 Q37283021-A730100B-C269-4A15-97EB-335CA7E516CB Q37394474-F1AD3327-3AEB-4F68-97E7-BE05379F7AD3 Q37701128-219A9DDB-51E2-4531-9430-7079E7EFCDCB Q38798449-73071F90-6448-4C05-9B2F-7A0CAB4A9172 Q39178447-B3D4F91D-66A1-490F-BB4F-295566BBA4D0 Q39941536-567AE1D0-5A76-428A-A55A-C317875B2B3F Q40678975-8B96DBDA-C88F-4371-BA95-A901AEF32BE5 Q41706349-5DBAF55F-4C75-40ED-80DC-FFC7BC65ACFE Q45330127-176D4F3F-FCA0-451D-9E35-47CF98F9A6A3 Q46415850-2FD85380-292D-45C8-A157-FCF59328C9A3 Q47138419-1BC46E85-7D5C-47C6-9A7C-649AA606EC69 Q52312048-E962F23D-A293-4475-8AFE-039F310A1A93 Q53736039-551A6BC6-ECEB-4519-9993-0E44BBE51C78

P2860

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.

http://www.wikidata.org/entity/Q33994570

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Application of a Physiological ...... rmacodynamics of Rosuvastatin.

@ast

Application of a Physiological ...... rmacodynamics of Rosuvastatin.

@en

type

label

Application of a Physiological ...... rmacodynamics of Rosuvastatin.

@ast

Application of a Physiological ...... rmacodynamics of Rosuvastatin.

@en

prefLabel

Application of a Physiological ...... rmacodynamics of Rosuvastatin.

@ast

Application of a Physiological ...... rmacodynamics of Rosuvastatin.

@en

P1433

Q33994570-F2AB4840-3CB5-438E-A727-464890F69086

P1476

Q33994570-D9C4E708-A019-4F8B-A111-E391031FB9C8

P2093

Q33994570-584B8F0F-E928-48EC-8722-04D06C6CC324

Q33994570-D03E184D-F8D2-4522-A54A-DAEB667AA5BD

Q33994570-D3A1F2AF-202D-425E-BE64-90D8F6002A63

Q33994570-FBB70C93-C528-419E-A4C1-1A40E88021E8

Q33994570-FBD26EBD-250C-4BCC-B3D6-B7E19EA38195

P2860

Q33994570-080D34A1-FE77-4577-9A3B-5094CC84B965

Q33994570-0B252DAA-BC60-4ADC-B9D5-CE05A5850F50

Q33994570-19F2346A-6446-4EAE-8ACD-66E1467E3D4C

Q33994570-1A689930-A2BC-404A-92BB-BB54E9480CA6

Q33994570-21793C34-DDAB-4B18-9A94-C662EFAFD949

Q33994570-2EC2CE52-9460-4F4A-BF0F-5FEC04D8841B

Q33994570-2F05CB45-179C-47AA-A7F7-081A8B04CB69

Q33994570-31D59489-67AB-407A-9D9A-78BB08503CDD

Q33994570-3480607F-3850-4AB0-9EDB-1300A2A6E8BA

Q33994570-3E080100-AE69-4DDD-925E-A3EE90EB8A06

P304

Q33994570-981428CB-498F-4FA0-9481-B7288448C25E

P31

Q33994570-A3E8E425-2F3A-4CFC-A275-4A402519321F

P356

Q33994570-9BB359B0-2D68-4C91-8E9A-D7427B990E34

P478

Q33994570-E48C172D-6DBD-4DC0-B8DC-794E688EA3D0

P50

Q33994570-CC0C79DD-6E7E-4C24-B2AC-CFAF79E4FB00

P577

Q33994570-4818E0A8-D367-457F-A507-6083961A4B17

P5875

Q33994570-E5CE0F33-EFCA-4F5B-B6D8-5579E19E8FBB

P698

Q33994570-5AA41629-ADDA-4A8F-BBB6-80BEADBFBFD5

P932

Q33994570-CD417DA7-5820-4EFE-8E79-41FCBAE2EA62

P356

P1433

CPT: pharmacometrics & systems pharmacology

P1476

Application of a Physiological ...... armacodynamics of Rosuvastatin

@en

P2093

A Rostami-Hodjegan

http://www.w3.org/2001/XMLSchema#string

K Abduljalil

http://www.w3.org/2001/XMLSchema#string

M Chetty

http://www.w3.org/2001/XMLSchema#string

M Jamei

http://www.w3.org/2001/XMLSchema#string

R H Rose

http://www.w3.org/2001/XMLSchema#string

P2860

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials.

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin.

P304

e124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/PSP.2014.24

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Sibylle Neuhoff

P577

2014-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263779058

http://www.w3.org/2001/XMLSchema#string

P698

25006781

http://www.w3.org/2001/XMLSchema#string

P932

4120018

http://www.w3.org/2001/XMLSchema#string